381 related articles for article (PubMed ID: 31636082)
1. Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG.
Iyer S; Sam FS; DiPrimio N; Preston G; Verheijen J; Murthy K; Parton Z; Tsang H; Lao J; Morava E; Perlstein EO
Dis Model Mech; 2019 Nov; 12(11):. PubMed ID: 31636082
[TBL] [Abstract][Full Text] [Related]
2. Sorbitol Is a Severity Biomarker for PMM2-CDG with Therapeutic Implications.
Ligezka AN; Radenkovic S; Saraswat M; Garapati K; Ranatunga W; Krzysciak W; Yanaihara H; Preston G; Brucker W; McGovern RM; Reid JM; Cassiman D; Muthusamy K; Johnsen C; Mercimek-Andrews S; Larson A; Lam C; Edmondson AC; Ghesquière B; Witters P; Raymond K; Oglesbee D; Pandey A; Perlstein EO; Kozicz T; Morava E
Ann Neurol; 2021 Dec; 90(6):887-900. PubMed ID: 34652821
[TBL] [Abstract][Full Text] [Related]
3. Yeast Models of Phosphomannomutase 2 Deficiency, a Congenital Disorder of Glycosylation.
Lao JP; DiPrimio N; Prangley M; Sam FS; Mast JD; Perlstein EO
G3 (Bethesda); 2019 Feb; 9(2):413-423. PubMed ID: 30530630
[TBL] [Abstract][Full Text] [Related]
4. Tracer metabolomics reveals the role of aldose reductase in glycosylation.
Radenkovic S; Ligezka AN; Mokashi SS; Driesen K; Dukes-Rimsky L; Preston G; Owuocha LF; Sabbagh L; Mousa J; Lam C; Edmondson A; Larson A; Schultz M; Vermeersch P; Cassiman D; Witters P; Beamer LJ; Kozicz T; Flanagan-Steet H; Ghesquière B; Morava E
Cell Rep Med; 2023 Jun; 4(6):101056. PubMed ID: 37257447
[TBL] [Abstract][Full Text] [Related]
5. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
Ramirez MA; Borja NL
Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
[TBL] [Abstract][Full Text] [Related]
6. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine.
Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H
J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319
[TBL] [Abstract][Full Text] [Related]
7. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
He J; Gao HX; Yang N; Zhu XD; Sun RB; Xie Y; Zeng CH; Zhang JW; Wang JK; Ding F; Aa JY; Wang GJ
Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
[TBL] [Abstract][Full Text] [Related]
8. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
Hotta N; Kawamori R; Fukuda M; Shigeta Y;
Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
[TBL] [Abstract][Full Text] [Related]
9. AZATAX: Acetazolamide safety and efficacy in cerebellar syndrome in PMM2 congenital disorder of glycosylation (PMM2-CDG).
Martínez-Monseny AF; Bolasell M; Callejón-Póo L; Cuadras D; Freniche V; Itzep DC; Gassiot S; Arango P; Casas-Alba D; de la Morena E; Corral J; Montero R; Pérez-Cerdá C; Pérez B; Artuch R; Jaeken J; Serrano M;
Ann Neurol; 2019 May; 85(5):740-751. PubMed ID: 30873657
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
Hotta N; Akanuma Y; Kawamori R; Matsuoka K; Oka Y; Shichiri M; Toyota T; Nakashima M; Yoshimura I; Sakamoto N; Shigeta Y
Diabetes Care; 2006 Jul; 29(7):1538-44. PubMed ID: 16801576
[TBL] [Abstract][Full Text] [Related]
11. International clinical guidelines for the management of phosphomannomutase 2-congenital disorders of glycosylation: Diagnosis, treatment and follow up.
Altassan R; Péanne R; Jaeken J; Barone R; Bidet M; Borgel D; Brasil S; Cassiman D; Cechova A; Coman D; Corral J; Correia J; de la Morena-Barrio ME; de Lonlay P; Dos Reis V; Ferreira CR; Fiumara A; Francisco R; Freeze H; Funke S; Gardeitchik T; Gert M; Girad M; Giros M; Grünewald S; Hernández-Caselles T; Honzik T; Hutter M; Krasnewich D; Lam C; Lee J; Lefeber D; Marques-de-Silva D; Martinez AF; Moravej H; Õunap K; Pascoal C; Pascreau T; Patterson M; Quelhas D; Raymond K; Sarkhail P; Schiff M; Seroczyńska M; Serrano M; Seta N; Sykut-Cegielska J; Thiel C; Tort F; Vals MA; Videira P; Witters P; Zeevaert R; Morava E
J Inherit Metab Dis; 2019 Jan; 42(1):5-28. PubMed ID: 30740725
[TBL] [Abstract][Full Text] [Related]
12. New and potential strategies for the treatment of PMM2-CDG.
Gámez A; Serrano M; Gallego D; Vilas A; Pérez B
Biochim Biophys Acta Gen Subj; 2020 Nov; 1864(11):129686. PubMed ID: 32712172
[TBL] [Abstract][Full Text] [Related]
13. Dietary mannose supplementation in phosphomannomutase 2 deficiency (PMM2-CDG).
Taday R; Grüneberg M; DuChesne I; Reunert J; Marquardt T
Orphanet J Rare Dis; 2020 Sep; 15(1):258. PubMed ID: 32962735
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological Chaperoning: A Potential Treatment for PMM2-CDG.
Yuste-Checa P; Brasil S; Gámez A; Underhaug J; Desviat LR; Ugarte M; Pérez-Cerdá C; Martinez A; Pérez B
Hum Mutat; 2017 Feb; 38(2):160-168. PubMed ID: 27774737
[TBL] [Abstract][Full Text] [Related]
15. Glycomic Characterization of Induced Pluripotent Stem Cells Derived from a Patient Suffering from Phosphomannomutase 2 Congenital Disorder of Glycosylation (PMM2-CDG).
Thiesler CT; Cajic S; Hoffmann D; Thiel C; van Diepen L; Hennig R; Sgodda M; Weiβmann R; Reichl U; Steinemann D; Diekmann U; Huber NM; Oberbeck A; Cantz T; Kuss AW; Körner C; Schambach A; Rapp E; Buettner FF
Mol Cell Proteomics; 2016 Apr; 15(4):1435-52. PubMed ID: 26785728
[TBL] [Abstract][Full Text] [Related]
16. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
Ando H; Takamura T; Nagai Y; Kaneko S;
J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
[TBL] [Abstract][Full Text] [Related]
17. Proteostasis regulators as potential rescuers of PMM2 activity.
Vilas A; Yuste-Checa P; Gallego D; Desviat LR; Ugarte M; Pérez-Cerda C; Gámez A; Pérez B
Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165777. PubMed ID: 32222543
[TBL] [Abstract][Full Text] [Related]
18. A mouse model of a human congenital disorder of glycosylation caused by loss of PMM2.
Chan B; Clasquin M; Smolen GA; Histen G; Powe J; Chen Y; Lin Z; Lu C; Liu Y; Cang Y; Yan Z; Xia Y; Thompson R; Singleton C; Dorsch M; Silverman L; Su SM; Freeze HH; Jin S
Hum Mol Genet; 2016 Jun; 25(11):2182-2193. PubMed ID: 27053713
[TBL] [Abstract][Full Text] [Related]
19. Neural and metabolic dysregulation in PMM2-deficient human in vitro neural models.
Radenkovic S; Budhraja R; Klein-Gunnewiek T; King AT; Bhatia TN; Ligezka AN; Driesen K; Shah R; Ghesquière B; Pandey A; Kasri NN; Sloan SA; Morava E; Kozicz T
Cell Rep; 2024 Mar; 43(3):113883. PubMed ID: 38430517
[TBL] [Abstract][Full Text] [Related]
20. Unsuccessful intravenous D-mannose treatment in PMM2-CDG.
Grünert SC; Marquardt T; Lausch E; Fuchs H; Thiel C; Sutter M; Schumann A; Hannibal L; Spiekerkoetter U
Orphanet J Rare Dis; 2019 Oct; 14(1):231. PubMed ID: 31640729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
